Dormant cancer cells and polyploid giant cancer cells: The roots of cancer recurrence and metastasis

Abstract

Tumour cell dormancy is critical for metastasis and resistance to chemoradiotherapy. Polyploid giant cancer cells (PGCCs) with giant or multiple nuclei and high DNA content have the properties of cancer stem cell and single PGCCs can individually generate tumours in immunodeficient mice. PGCCs represent a dormant form of cancer cells that survive harsh tumour conditions and contribute to tumour recurrence. Hypoxic mimics, chemotherapeutics, radiation and cytotoxic traditional Chinese medicines can induce PGCCs formation through endoreduplication and/or cell fusion. After incubation, dormant PGCCs can recover from the treatment and produce daughter cells with strong proliferative, migratory and invasive abilities via asymmetric cell division. Additionally, PGCCs can resist hypoxia or chemical stress and have a distinct protein signature that involves chromatin remodelling and cell cycle regulation. Dormant PGCCs form the cellular basis for therapeutic resistance, metastatic cascade and disease recurrence. This review summarises regulatory mechanisms governing dormant cancer cells entry and exit of dormancy, which may be used by PGCCs, and potential therapeutic strategies for targeting PGCCs.

Keywords

cell cycle arrest / dormancy / endoreduplication / polyploid giant cancer cells

References

[1] Willis RA. The Spread of Tumours in the Human Body. London, J. & A. Chuchill; 1934.

[2] Hadfield G. The dormant cancer cell. Br Med J. 1954;2(4888):607-610.

[3] Saad N, Alberio R, Johnson AD, et al. Cancer reversion with oocyte extracts is mediated by cell cycle arrest and induction of tumour dormancy. Oncotarget. 2018;9(22):16008-16027.

[4] Vitetta ES, Tucker TF, Racila E, et al. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood. 1997;89(12):4425-4436.

[5] Guo F, Yuan D, Zhang J, et al. Silencing of ARL14 gene induces lung adenocarcinoma cells to a dormant state. Front Cell Dev Biol. 2019;7:238.

[6] Baldominos P, Barbera-Mourelle A, Barreiro O, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694-1708. e1619.

[7] Lawson MA, McDonald MM, Kovacic N, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.

[8] Fane ME, Chhabra Y, Alicea GM, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2022;606(7913):396-405.

[9] Perego M, Tyurin VA, Tyurina YY, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med. 2020;12(572):eabb5817.

[10] Zhang S, Mercado-Uribe I, Liu J: Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Lett. 2013;333(2):205-212.

[11] Fei F, Zhang M, Li B, et al. Formation of polyploid giant cancer cells involves in the prognostic value of neoadjuvant chemoradiation in locally advanced rectal cancer. J Oncol. 2019;2019:2316436.

[12] Mallin MM, Kim N, Choudhury MI, et al. Cells in the polyaneuploid cancer cell (PACC) state have increased metastatic potential. Clin Exp Metastasis. 2023;40(4):321-338.

[13] Mirzayans R, Andrais B, Scott A, Wang YW, Kumar P, Murray D. Multinucleated giant cancer cells produced in response to ionizing radiation retain viability and replicate their genome. Int J Mol Sci. 2017;18(2):360.

[14] Adams DL, Martin SS, Alpaugh RK, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci USA. 2014;111(9):3514-3519.

[15] Liu Y, Shi Y, Wu M, et al. Hypoxia-induced polypoid giant cancer cells in glioma promote the transformation of tumor-associated macrophages to a tumor-supportive phenotype. CNS Neurosci Ther. 2022;28(9):1326-1338.

[16] White-Gilbertson S, Voelkel-Johnson C. Giants and monsters: Unexpected characters in the story of cancer recurrence. Adv Cancer Res. 2020;148:201-232.

[17] Pienta KJ, Hammarlund EU, Brown JS, Amend SR, Axelrod RM. Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proc Natl Acad Sci USA. 2021;118(7):e2020838118.

[18] Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene. 2014;33(1):116-128.

[19] Zhang Z, Feng X, Deng Z, et al. Irradiation-induced polyploid giant cancer cells are involved in tumor cell repopulation via neosis. Mol Oncol. 2021;15(8):2219-2234.

[20] Li Z, Zheng M, Zhang H, et al. Arsenic trioxide promotes tumor progression by inducing the formation of PGCCs and embryonic hemoglobin in colon cancer cells. Front Oncol. 2021;11:720814.

[21] Cheng T, Zhang S, Xia T, et al. EBV promotes vascular mimicry of dormant cancer cells by potentiating stemness and EMT. Exp Cell Res. 2022;421(2):113403.

[22] Zhang X, Yao J, Li X, et al. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023;9(29):eadf7195.

[23] You B, Xia T, Gu M, et al. AMPK-mTOR-mediated activation of autophagy promotes formation of dormant polyploid giant cancer cells. Cancer Res. 2022;82(5):846-858.

[24] Xuan B, Ghosh D, Jiang J, Shao R, Dawson MR. Vimentin filaments drive migratory persistence in polyploidal cancer cells. Proc Natl Acad Sci USA. 2020;117(43):26756-26765.

[25] Liu K, Lu R, Zhao Q, et al. Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation. Med Oncol. 2019;37(1):6.

[26] Chen J, Niu N, Zhang J, et al. Polyploid giant cancer cells (PGCCs): the evil roots of cancer. Curr Cancer Drug Targets. 2019;19(5):360-367.

[27] Braune EB, Tsoi YL, Phoon YP, et al. Loss of CSL unlocks a hypoxic response and enhanced tumor growth potential in breast cancer cells. Stem Cell Rep. 2016;6(5):643-651.

[28] Rhodes A, Hillen T. Implications of immune-mediated metastatic growth on metastatic dormancy, blow-up, early detection, and treatment. J Math Biol. 2020;8 1(3):799-843.

[29] Kareva I. Primary and metastatic tumor dormancy as a result of population heterogeneity. Biol Direct. 2016;11(1):37.

[30] Wheeler SE, Clark AM, Taylor DP, et al. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer. 2014;111(12):2342-2350.

[31] Hosseini H, Obradovic MMS, Hoffmann M, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016;540(7634):552-558.

[32] Borgen E, Rypdal MC, Sosa MS, et al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Res. 2018;20(1):120.

[33] Matson JP, House AM, Grant GD, Wu H, Perez J, Cook JG. Intrinsic checkpoint deficiency during cell cycle re-entry from quiescence. J Cell Biol. 2019;218(7):2169-2184.

[34] Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. PLoS Biol. 2006;4(3):e83.

[35] Nobre AR, Risson E, Singh DK, et al. Bone marrow NG2(+)/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGFbeta2. Nat Cancer. 2021;2(3):327-339.

[36] Wang L, Peng Q, Xie Y, et al. Cell-cell contact-driven EphB1 cis- and trans- signalings regulate cancer stem cells enrichment after chemotherapy. Cell Death Dis. 2022;13(11):980.

[37] Murayama T, Takeuchi Y, Yamawaki K, et al. MCM10 compensates for Myc-induced DNA replication stress in breast cancer stem-like cells. Cancer Sci. 2021;112(3):1209-1224.

[38] Saijoh S, Nakamura-Shima M, Shibuya-Takahashi R, et al. Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein. Biochem Biophys Res Commun. 2021;537:132-139.

[39] Trotter TN, Dagotto CE, Serra D, et al. Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3. JCI Insight. 2023;8(22):e174458.

[40] Damen MPF, van Rheenen J, Scheele C. Targeting dormant tumor cells to prevent cancer recurrence. FEBS J. 2021;288(21):6286-6303.

[41] Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle. 2006;5(16):1744-1750.

[42] Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298-306.

[43] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-1437.

[44] Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24(2):277-283.

[45] Sosa MS, Parikh F, Maia AG, et al. NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven quiescence programmes. Nat Commun. 2015;6:6170.

[46] Nobre AR, Dalla E, Yang J, et al. ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung. Nat Cancer. 2022;3(10):1165-1180.

[47] Mukherjee A, Bravo-Cordero JJ. Regulation of dormancy during tumor dissemination: the role of the ECM. Cancer Metastasis Rev. 2023;42(1):99-112.

[48] Liu Y, Zhang P, Wu Q, et al. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and DeltaNp63. Nat Commun. 2021;12(1):5232.

[49] Sun D, Singh DK, Carcamo S, et al. MacroH2A impedes metastatic growth by enforcing a discrete dormancy program in disseminated cancer cells. Sci Adv. 2022;8(48):eabo0876.

[50] Lim PK, Bliss SA, Patel SA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011;71(5):1550-1560.

[51] Han Y, Villarreal-Ponce A, Gutierrez G, et al. Coordinate control of basal epithelial cell fate and stem cell maintenance by core EMT transcription factor Zeb1. Cell Rep. 2022;38(2):110240.

[52] Dai Y, Wang L, Tang J, et al. Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress. Oncotarget. 2016;7(18):25478-25492.

[53] Meng X, Xiao W, Sun J, et al. CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. Cancer Lett. 2023;554:216023.

[54] Dou R, Liu K, Yang C, et al. EMT-cancer cells-derived exosomal miR-27b-3p promotes circulating tumour cells-mediated metastasis by modulating vascular permeability in colorectal cancer. Clin Transl Med. 2021;11(12):e595.

[55] Tejero R, Huang Y, Katsyv I, et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. EBioMedicine. 2019;42:252-269.

[56] Correia AL, Guimaraes JC, Auf der Maur P, et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594(7864):566-571.

[57] Lenk L, Pein M, Will O, et al. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Oncoimmunology. 2017;7(1):e1368603.

[58] Recasens A, Munoz L. Targeting cancer cell dormancy. Trends Pharmacol Sci. 2019;40(2):128-141.

[59] Fox DB, Garcia NMG, McKinney BJ, et al. NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. Nat Metab. 2020;2(4):318-334.

[60] Kutay M, Gozuacik D, Cakir T. Cancer recurrence and omics: metabolic signatures of cancer dormancy revealed by transcriptome mapping of genome-scale networks. OMICS. 2022;26(5):270-279.

[61] Brunel A, Hombourger S, Barthout E, et al. Autophagy inhibition reinforces stemness together with exit from dormancy of polydisperse glioblastoma stem cells. Aging (Albany NY). 2021;13(14):18106-18130.

[62] Bakhshandeh S, Werner C, Fratzl P, Cipitria A. Microenvironment-mediated cancer dormancy: Insights from metastability theory. Proc Natl Acad Sci USA. 2022;119(1):e2111046118.

[63] Chernosky NM, Tamagno I. The role of the innate immune system in cancer dormancy and relapse. Cancers (Basel). 2021;13(22):5621.

[64] Zhu X, Wang F, Wu X, et al. FBX8 promotes metastatic dormancy of colorectal cancer in liver. Cell Death Dis. 2020;11(8):622.

[65] Weston WA, Barr AR. A cell cycle centric view of tumour dormancy. Br J Cancer. 2023;129(10):1535-1545.

[66] Pustovalova M, Blokhina T, Alhaddad L, et al. CD44+ and CD133+ non-small cell lung cancer cells exhibit DNA damage response pathways and dormant polyploid giant cancer cell enrichment relating to their p53 status. Int J Mol Sci. 2022;23(9):4922.

[67] Pellicano F, Scott MT, Helgason GV, et al. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells. 2014;32(9):2324-2337.

[68] Dhimolea E, de Matos Simoes R, Kansara D, et al. An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell. 2021;39(2):240-256. e211.

[69] La T, Chen S, Guo T, et al. Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells. Theranostics. 2021;11(19):9605-9622.

[70] Wu R, Roy AM, Tokumaru Y, et al. NR2F1, a tumor dormancy marker, is expressed predominantly in cancer-associated fibroblasts and is associated with suppressed breast cancer cell proliferation. Cancers (Basel). 2022;14(12):2962.

[71] Haldar R, Berger LS, Rossenne E, et al. Perioperative escape from dormancy of spontaneous micro-metastases: A role for malignant secretion of IL-6, IL-8, and VEGF, through adrenergic and prostaglandin signaling. Brain Behav Immun. 2023;109:175-187.

[72] O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2(6):689-692.

[73] Katayama N, Clark SC, Ogawa M. Growth factor requirement for survival in cell-cycle dormancy of primitive murine lymphohematopoietic progenitors. Blood. 1993;81(3):610-616.

[74] Qiu Y, Qiu S, Deng L, et al. Biomaterial 3D collagen I gel culture model: A novel approach to investigate tumorigenesis and dormancy of bladder cancer cells induced by tumor microenvironment. Biomaterials. 2020;256:120217.

[75] Decker AM, Decker JT, Jung Y, et al. Adrenergic blockade promotes maintenance of dormancy in prostate cancer through upregulation of GAS6. Transl Oncol. 2020;13(7):100781.

[76] Clements ME, Holtslander L, Edwards C, et al. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. Oncogene. 2021;40(34):5314-5326.

[77] Tivari S, Lu H, Dasgupta T, De Lorenzo MS, Wieder R. Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence. Cell Commun Signal. 2018;16(1):48.

[78] Rajbhandari N, Lin WC, Wehde BL, Triplett AA, Wagner KU. Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers. Cell Rep. 2017;18(9):2243-2255.

[79] Winkler IG, Barbier V, Nowlan B, et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012;18(11):1651-1657.

[80] Kobayashi A, Okuda H, Xing F, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011;208(13):2641-2655.

[81] Guereno M, Delgado Pastore M, Lugones AC, et al. Glypican-3 (GPC3) inhibits metastasis development promoting dormancy in breast cancer cells by p38 MAPK pathway activation. Eur J Cell Biol. 2020;99(6):151096.

[82] Soureas K, Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, Avgeris M. Cancer quiescence: non-coding RNAs in the spotlight. Trends Mol Med. 2023;29(10):843-858.

[83] Nagayama Y, Shigematsu K, Namba H, Zeki K, Yamashita S, Niwa M. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res. 2000;20(4):2723-2728.

[84] Holmgren L, Jackson G, Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene. 1998;17(7):819-824.

[85] Itahana K, Dimri GP, Hara E, et al. A role for p53 in maintaining and establishing the quiescence growth arrest in human cells. J Biol Chem. 2002;277(20):18206-18214.

[86] La T, Liu GZ, Farrelly M, et al. A p53-responsive miRNA network promotes cancer cell quiescence. Cancer Res. 2018;78(23):6666-6679.

[87] Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005;65(7):2795-2803.

[88] Yu-Lee LY, Yu G, Lee YC, et al. Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway. Cancer Res. 2018;78(11):2911-2924.

[89] Sailo BL, Banik K, Girisa S, et al. FBXW7 in cancer: what has been unraveled thus far?Cancers (Basel). 2019;11(2):246.

[90] Bragado P, Estrada Y, Parikh F, et al. TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 2013;15(11):1351-1361.

[91] Prunier C, Baker D, Ten Dijke P, Ritsma L. TGF-beta family signaling pathways in cellular dormancy. Trends Cancer. 2019;5(1):66-78.

[92] Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, Wilson EL. TGF-beta maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol. 2005;170(1):81-90.

[93] Singh DK, Carcamo S, Farias EF, et al. 5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-beta-SMAD4 signaling. Cell Rep. 2023;42(6):112560.

[94] Mao W, Peters HL, Sutton MN, et al. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer. 2019;125(8):1267-1280.

[95] Li B, Huang Y, Ming H, Nice EC, Xuan R, Huang C. Redox control of the dormant cancer cell life cycle. Cells. 2021;10(10):2707.

[96] Barney LE, Hall CL, Schwartz AD, et al. Tumor cell-organized fibronectin maintenance of a dormant breast cancer population. Sci Adv. 2020;6(11):eaaz4157.

[97] Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66-77.

[98] Hu J, Sanchez-Rivera FJ, Wang Z, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023;616(7958):806-813.

[99] Sharma S, Xing F, Liu Y, et al. Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate cancer in bone. J Biol Chem. 2016;291(37):19351-19363.

[100] Sharma S, Pei X, Xing F, et al. Regucalcin promotes dormancy of prostate cancer. Oncogene. 2021;40(5):1012-1026.

[101] Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001;12(4):863-879.

[102] Keeratichamroen S, Lirdprapamongkol K, Svasti J. Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells. Oncol Rep. 2018;39(4):1765-1774.

[103] Sunderland A, Williams J, Andreou T, et al. Biglycan and reduced glycolysis are associated with breast cancer cell dormancy in the brain. Front Oncol. 2023;13:1191980.

[104] Valcourt JR, Lemons JM, Haley EM, Kojima M, Demuren OO, Coller HA. Staying alive: metabolic adaptations to quiescence. Cell Cycle. 2012;11(9):1680-1696.

[105] Ameri K, Jahangiri A, Rajah AM, et al. HIGD1A regulates oxygen consumption, ROS production, and AMPK activity during glucose deprivation to modulate cell survival and tumor growth. Cell Rep. 2015;10(6):891-899.

[106] Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003;63(7):1684-1695.

[107] Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006;66(3):1702-1711.

[108] Esposito A, Ferraresi A, Salwa A, Vidoni C, Dhanasekaran DN, Isidoro C. Resveratrol contrasts IL-6 pro-growth effects and promotes autophagy-mediated cancer cell dormancy in 3D ovarian cancer: role of miR-1305 and of its target ARH-I. Cancers (Basel). 2022;14(9):2142.

[109] Han B, Chen Y, Song C, et al. Autophagy modulates the stability of Wee1 and cell cycle G2/M transition. Biochem Biophys Res Commun. 2023;677:63-69.

[110] Zhou J, Jiang YY, Chen H, Wu YC, Zhang L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12739.

[111] Liu JZ, Hu YL, Feng Y, et al. BDH2 triggers ROS-induced cell death and autophagy by promoting Nrf2 ubiquitination in gastric cancer. J Exp Clin Cancer Res. 2020;39(1):123.

[112] Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008;118(12):3917-3929.

[113] Tian X, He Y, Qi L, et al. Autophagy inhibition contributes to apoptosis of PLK4 downregulation-induced dormant cells in colorectal cancer. Int J Biol Sci. 2023;19(9):2817-2834.

[114] Vera-Ramirez L, Hunter KW. Tumor cell dormancy as an adaptive cell stress response mechanism. F1000Res. 2017;6:2134.

[115] Liu Z, Liu G, Ha DP, Wang J, Xiong M, Lee AS. ER chaperone GRP78/BiP translocates to the nucleus under stress and acts as a transcriptional regulator. Proc Natl Acad Sci USA. 2023;120(31):e2303448120.

[116] Wang Z, Tan C, Duan C, et al. FUT2-dependent fucosylation of HYOU1 protects intestinal stem cells against inflammatory injury by regulating unfolded protein response. Redox Biol. 2023;60:102618.

[117] You K, Wang L, Chou CH, et al. QRICH1 dictates the outcome of ER stress through transcriptional control of proteostasis. Science. 2021l371(6524):eabb6896.

[118] Cho J, Min HY, Lee HJ, et al. RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. J Clin Invest. 2023;133(10):e171901.

[119] Liu Y, Lv J, Liang X, et al. Fibrin stiffness mediates dormancy of tumor-repopulating cells via a Cdc42-driven Tet2 epigenetic program. Cancer Res. 2018;78(14):3926-3937.

[120] Ruppender N, Larson S, Lakely B, et al. Cellular adhesion promotes prostate cancer cells escape from dormancy. PLoS One. 2015;10(6):e0130565.

[121] Lopez-Sanchez LM, Jimenez C, Valverde A, et al. CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer. PLoS One. 2014;9(6):e99143.

[122] Zhao S, Xing S, Wang L, et al. IL-1beta is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer. Sci Rep. 2023;13(1):12763.

[123] Zheng M, Chen L, Fu J, et al. Cdc42 regulates the expression of cytoskeleton and microtubule network proteins to promote invasion and metastasis of progeny cells derived from CoCl(2)-induced polyploid giant cancer cells. J Cancer. 2023;14(10):1920-1934.

[124] Zhang K, Yang X, Zheng M, Ning Y, Zhang S. Acetylated-PPARgamma expression is regulated by different P53 genotypes associated with the adipogenic differentiation of polyploid giant cancer cells with daughter cells. Cancer Biol Med. 2023;20(1):56-76.

[125] Zhou X, Zhou M, Zheng M, et al. Polyploid giant cancer cells and cancer progression. Front Cell Dev Biol. 2022;10:1017588.

[126] Liu K, Zheng M, Zhao Q, et al. Different p53 genotypes regulating different phosphorylation sites and subcellular location of CDC25C associated with the formation of polyploid giant cancer cells. J Exp Clin Cancer Res. 2020;39(1):83.

[127] Alhaddad L, Chuprov-Netochin R, Pustovalova M, Osipov AN, Leonov S. Polyploid/multinucleated giant and slow-cycling cancer cell enrichment in response to x-ray irradiation of human glioblastoma multiforme cells differing in radioresistance and TP53/PTEN status. Int J Mol Sci. 2023;24(2):1228.

[128] Miller I, Min M, Yang C, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24(5):1105-1112. e1105.

[129] Davis JE, Kirk J, Ji Y, Tang DG. Tumor dormancy and slow-cycling cancer cells. Adv Exp Med Biol. 2019;1164:199-206.

[130] DeLuca VJ, Saleh T. Insights into the role of senescence in tumor dormancy: mechanisms and applications. Cancer Metastasis Rev. 2023;42(1):19-35.

[131] Akkoc Y, Peker N, Akcay A, Gozuacik D. Autophagy and cancer dormancy. Front Oncol. 2021;11:627023.

[132] Clezardin P, Coleman R, Puppo M, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101(3):797-855.

[133] Endo H, Inoue M. Dormancy in cancer. Cancer Sci. 2019;110(2):474-480.

[134] Xuan B, Ghosh D, Cheney EM, Clifton EM, Dawson MR. Dysregulation in actin cytoskeletal organization drives increased stiffness and migratory persistence in polyploidal giant cancer cells. Sci Rep. 2018;8(1):11935.

[135] Zhang S, Mercado-Uribe I, Hanash S, Liu J. iTRAQ-based proteomic analysis of polyploid giant cancer cells and budding progeny cells reveals several distinct pathways for ovarian cancer development. PLoS One. 2013;8(11):e80120.

[136] Puig PE, Guilly MN, Bouchot A, et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int. 2008;32(9):1031-1043.

[137] White-Gilbertson S, Lu P, Norris JS, Voelkel-Johnson C. Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis. J Lipid Res. 2019;60(7):1225-1235.

[138] Niu N, Mercado-Uribe I, Liu J. Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene. 2017;36(34):4887-4900.

[139] Niu N, Zhang J, Zhang N, et al. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis. 2016;5(12):e281.

[140] Richards JS, Candelaria NR, Lanz RB. Polyploid giant cancer cells and ovarian cancer: new insights into mitotic regulators and polyploidydagger. Biol Reprod. 2021;105(2):305-316.

[141] Casotti MC, Meira DD, Zetum ASS, et al. Computational biology helps understand how polyploid giant cancer cells drive tumor success. Genes (Basel). 2023;14(4):801.

[142] White-Gilbertson S, Lu P, Jones CM, et al. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis. Cancer Med. 2020;9(9):3142-3152.

[143] Liu HT, Xia T, You YW, et al. Characteristics and clinical significance of polyploid giant cancer cells in laryngeal carcinoma. Laryngoscope Investig Otolaryngol. 2021;6(5):1228-1234.

[144] Schwarz EM, Roeder AH. Transcriptomic effects of the cell cycle regulator LGO in arabidopsis sepals. Front Plant Sci. 2016;7:1744.

[145] Wang J, Batourina E, Schneider K, et al. Polyploid superficial cells that maintain the urothelial barrier are produced via incomplete cytokinesis and endoreplication. Cell Rep. 2018;25(2):464-477. e464.

[146] Fei F, Qu J, Liu K, et al. The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance. Lab Invest. 2019;99(4):483-498.

[147] Min M, Spencer SL. Spontaneously slow-cycling subpopulations of human cells originate from activation of stress-response pathways. PLoS Biol. 2019;17(3):e3000178.

[148] Zhang J, Qiao Q, Xu H, Zhou R, Liu X. Human cell polyploidization: the good and the evil. Semin Cancer Biol. 2022;81:54-63.

[149] Fei F, Zhang D, Yang Z, et al. The number of polyploid giant cancer cells and epithelial-mesenchymal transition-related proteins are associated with invasion and metastasis in human breast cancer. J Exp Clin Cancer Res. 2015;34:158.

[150] Lin KC, Torga G, Sun Y, et al. The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells. Clin Exp Metastasis. 2019;36(2):97-108.

[151] Glassmann A, Carrillo Garcia C, Janzen V, et al. Staurosporine induces the generation of polyploid giant cancer cells in non-small-cell lung carcinoma A549 cells. Anal Cell Pathol (Amst). 2018;2018:1754085.

[152] Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167-197.

[153] de Groot AE, Roy S, Brown JS, Pienta KJ, Amend SR. Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis. Mol Cancer Res. 2017;15(4):361-370.

[154] Heng J, Heng HH. Genome chaos: Creating new genomic information essential for cancer macroevolution. Semin Cancer Biol. 2022;81:160-175.

[155] Kostecka LG, Pienta KJ, Amend SR. Polyaneuploid cancer cell dormancy: lessons from evolutionary phyla. Front Ecol Evol. 2021;9:660755.

[156] Adibi R, Moein S, Gheisari Y. Zoledronic acid targets chemo-resistant polyploid giant cancer cells. Sci Rep. 2023;13(1):419.

[157] El Baba R, Pasquereau S, Haidar Ahmad S, Diab-Assaf M, Herbein G. Oncogenic and stemness signatures of the high-risk HCMV strains in breast cancer progression. Cancers (Basel). 2022;14(17):4271.

[158] Mejia Pena C, Skipper TA, Hsu J, Schechter I, Ghosh D, Dawson MR. Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations. Sci Rep. 2023;13(1):19232.

[159] Mukherjee S, Ali AM, Murty VV, Raza A. Mutation in SF3B1 gene promotes formation of polyploid giant cells in leukemia cells. Med Oncol. 2022;39(5):65.

[160] Kondorosi E, Roudier F, Gendreau E. Plant cell-size control: growing by ploidy?Curr Opin Plant Biol. 2000, 3(6):488-492.

[161] Lv H, Shi Y, Zhang L, et al. Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC Cancer. 2014;14:576.

[162] Lu P, White-Gilbertson S, Beeson G, et al. Ceramide synthase 6 maximizes p53 function to prevent progeny formation from polyploid giant cancer cells. Cancers (Basel). 2021;13(9):2212.

[163] Fu F, Chen L, Yang X, et al. PLK4 is a key molecule in the formation of PGCCs and promotes invasion and migration of progeny cells derived from PGCCs. J Cancer. 2022;13(9):2954-2969.

[164] Zhao Q, Zhang K, Li Z, et al. High migration and invasion ability of PGCCs and their daughter cells associated with the nuclear localization of S100A10 modified by SUMOylation. Front Cell Dev Biol. 2021;9:696871.

[165] Fei F, Liu K, Li C, et al. Molecular mechanisms by which S100A4 regulates the migration and invasion of PGCCs with their daughter cells in human colorectal cancer. Front Oncol. 2020;10:182.

[166] Wang X, Zheng M, Fei F, et al. EMT-related protein expression in polyploid giant cancer cells and their daughter cells with different passages after triptolide treatment. Med Oncol. 2019;36(9):82.

[167] Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715.

[168] Fan L, Zheng M, Zhou X, et al. Molecular mechanism of vimentin nuclear localization associated with the migration and invasion of daughter cells derived from polyploid giant cancer cells. J Transl Med. 2023;21(1):719.

[169] Parekh A, Das S, Parida S, et al. Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene. 2018;37(33):4546-4561.

[170] Saini G, Joshi S, Garlapati C, et al. Polyploid giant cancer cell characterization: new frontiers in predicting response to chemotherapy in breast cancer. Semin Cancer Biol. 2022;81:220-231.

[171] Haidar Ahmad S, El Baba R, Herbein G: Polyploid giant cancer cells, cytokines and cytomegalovirus in breast cancer progression. Cancer Cell Int. 2023;23(1):119.

[172] Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis. 2021;10(9):65.

[173] Xuan B, Ghosh D, Dawson MR. Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression. Semin Cancer Biol. 2022;81:64-72.

[174] Mirzayans R, Murray D. Intratumor heterogeneity and treatment resistance of solid tumors with a focus on polyploid/senescent giant cancer cells (PGCCs). Int J Mol Sci. 2023;24(14):11534.

[175] Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398-411.

[176] Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors. Cell. 2020;183(4):860-874.

[177] Zhang D, Yang X, Yang Z, et al. Daughter cells and erythroid cells budding from PGCCs and their clinicopathological significances in colorectal cancer. J Cancer. 2017;8(3):469-478.

[178] Tagal V, Roth MG. Loss of aurora kinase signaling allows lung cancer cells to adopt endoreplication and form polyploid giant cancer cells that resist antimitotic drugs. Cancer Res. 2021;81(2):400-413.

[179] Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407-419.

[180] Bai S, Taylor SE, Jamalruddin MA, et al. Targeting therapeutic resistance and multinucleate giant cells in CCNE1-amplified HR-proficient ovarian cancer. Mol Cancer Ther. 2022;21(9):1473-1484.

[181] Bowers RR, Andrade MF, Jones CM, White-Gilbertson S, Voelkel-Johnson C, Delaney JR. Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs). BMC Cancer. 2022;22(1):410.

[182] Thura M, Ye Z, Al-Aidaroos AQ, et al. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. Commun Biol. 2021;4(1):923.

[183] Ishay-Ronen D, Diepenbruck M, Kalathur RKR, et al. Gain fat-lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 2019;35(1):17-32. e16.

[184] Li X, Zhong Y, Zhang X, Sood AK, Liu J. Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. Oncogene. 2023;42(9):665-678.

[185] Zhang L, Ding P, Lv H, et al. Number of polyploid giant cancer cells and expression of EZH2 are associated with VM formation and tumor grade in human ovarian tumor. Biomed Res Int. 2014;2014:903542.

[186] Yart L, Bastida-Ruiz D, Allard M, Dietrich PY, Petignat P, Cohen M. Linking unfolded protein response to ovarian cancer cell fusion. BMC Cancer. 2022;22(1):622.

[187] Xu H, Zeng S, Wang Y, et al. Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells. J Pathol. 2023;261(2):210-226.

[188] Adibi R, Moein S, Gheisari Y. Cisplatin-resistant ovarian cancer cells reveal a polyploid phenotype with remarkable activation of nuclear processes. Adv Biomed Res. 2023;12:77.

[189] Zhang S, Mercado-Uribe I, Liu J. Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer. 2014;134(3):508-518.

[190] Nehme Z, Pasquereau S, Haidar Ahmad S, et al. Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus. Oncogene. 2021;40(17):3030-3046.

[191] Nehme Z, Pasquereau S, Haidar Ahmad S, El Baba R, Herbein G. Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus. EBioMedicine. 2022;80:104056.

[192] Liu G, Wang Y, Fei F, et al. Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas. Melanoma Res. 2018;28(6):592-599.

[193] Kaibori Y, Nagakubo D. CCR3 blockage elicits polyploidization associated with the signatures of epithelial-mesenchymal transition in carcinoma cell lines. Cancer Gene Ther. 2023;30(1):137-148.

[194] Peerapen P, Sueksakit K, Boonmark W, Yoodee S, Thongboonkerd V. ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An in vitro cellular mechanism study. J Cancer. 2022;13(2):373-384.

[195] Fei F, Li C, Cao Y, et al. CK7 expression associates with the location, differentiation, lymph node metastasis, and the Dukes' stage of primary colorectal cancers. J Cancer. 2019;10(11):2510-2519.

[196] Qu Y, Zhang L, Rong Z, He T, Zhang S. Number of glioma polyploid giant cancer cells (PGCCs) associated with vasculogenic mimicry formation and tumor grade in human glioma. J Exp Clin Cancer Res. 2013;32(1):75.

[197] Mi R, Ji J, Zhang M, et al. Establishment of the glioma polyploid giant cancer cell model by a modified PHA-DMSO-PEG fusion method following dual drug-fluorescence screening in vitro. J Neurosci Methods. 2022;368:109462.

[198] Bouezzedine F, El Baba R, Haidar Ahmad S, Herbein G. Polyploid giant cancer cells generated from human cytomegalovirus-infected prostate epithelial cells. Cancers (Basel). 2023;15(20):4994.

[199] Patra S, Singh A, Praharaj PP, et al. SIRT1 inhibits mitochondrial hyperfusion associated mito-bulb formation to sensitize oral cancer cells for apoptosis in a mtROS-dependent signalling pathway. Cell Death Dis. 2023;14(11):732.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.